Gilead Sciences reported $2.55 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 2.55 2.23 2.47 Oct/29
FY2026Q2 Jun/2026 -6.75 -7.32 2.01 Aug/04
FY2026Q1 Mar/2026 2.03 1.9 1.81 May/07
FY2025Q4 Dec/2025 1.86 1.89 1.90 Feb/10
FY2025Q3 Sep/2025 2.47 2.16 2.02 Oct/30




Eps Change Date
AbbVie USD 3.82 0.17 Sep/2026
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
ALKERMES USD 0.09 0.09 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
Biogen USD 2.62 0.98 Sep/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Bristol-Myers Squibb USD 1.35 0.69 Sep/2026
Coherus Biosciences USD -0.43 0.06 Dec/2025
Eli Lilly USD 7.48 0.9 Sep/2026
Gilead Sciences USD 2.55 9.3 Sep/2026
GlaxoSmithKline GBP 0.55 0.04 Sep/2026
Glaxosmithkline GBP 0.76 0.14 Sep/2026
Incyte USD -3.6 6.69 Sep/2026
J&J USD 2.7 0.2 Sep/2026
Merck USD 2.49 2.62 Sep/2026
Moderna USD 0.38 2.35 Sep/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
Novartis USD 2.46 0.05 Sep/2026
Pfizer USD 0.87 0.1 Sep/2026
PTC Therapeutics USD -0.62 1.54 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sanofi EUR 3.55 1.46 Sep/2026
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
United Therapeutics USD 5.71 1.56 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026